Biosimilars, Biologics Manufacturing, mAbs, Recombinant Proteins & Emerging-Cell-and-Gene-Therapy Leadership
Biosimilars & Biologics
Executive Search
40+ Biosimilars & Biologics Placements — with an average 98 Days time-to-placement and a 12-month candidate guarantee.
40+
Biosimilars & Biologics Placements
98 Days
Avg. Time-to-Placement
89%
Offer Acceptance Rate
12 Months
Candidate Guarantee
Specialisation withinPharmaceuticals & Biotechnology·Innovating for Better Health
Biosimilars-and-biologics represents the highest-value-per-molecule pharma tranche and India's emerging global competitive-position in biologics manufacturing and biosimilar development. The ecosystem spans listed biosimilar and biologics majors (the market-leading listed Indian biosimilars specialist with a comprehensive portfolio, the biologics arms of listed large-cap Indian pharma majors, and listed biosimilars-and-biologics arms of integrated listed pharma majors), pure-play biologics CDMOs (listed CRO-and-CDMO biologics specialists, listed integrated-biopharma manufacturing-and-vaccines operators, and privately-held biologics manufacturers), contract-research-and-manufacturing biologics specialists, recombinant-protein specialists (India units of global biologics MNCs, listed Indian biologics-and-vaccines specialists), monoclonal-antibody (mAb) specialists, emerging cell-and-gene-therapy specialists (India-domiciled cell-and-gene-therapy ventures and adjacent research-linked ventures), and emerging antibody-drug-conjugate (ADC) specialists. Leadership here requires fluency in biologics-manufacturing architecture (mammalian-cell-culture, microbial-fermentation), biosimilar-development-and-comparability protocol stewardship, WHO-prequalification and USFDA / EMA biosimilar-pathway compliance, cold-chain-and-supply-chain architecture, and the specific IP-and-patent-and-exclusivity architecture that defines biosimilar economics.
Is This Your Situation?
If any of these sound familiar, you're speaking to the right practice.
→Listed biosimilar-and-biologics major running CEO succession — confidential search with promoter and nomination-committee alignment across biosimilar-and-biologics operating credibility, multi-product global-pipeline stewardship, and listed-group governance.
→Pure-play biologics CDMO scaling its global-pharma-customer programme hiring a Head of Bioprocessing with upstream-and-downstream bioprocessing credibility and the specific mammalian-cell-culture-and-aseptic-fill-finish architecture.
→Listed biosimilar operator preparing for a US-biosimilar launch hiring a Head of Commercialisation with US-biosimilar-launch credibility and the specific partnership-and-wholesaler architecture.
→Emerging cell-and-gene-therapy specialist running a scale-up and series-B / growth-equity round hiring a CEO with cell-and-gene-therapy development credibility and the specific investor-cadence architecture.
Our Biosimilars & Biologics Track Record
Situation:
A listed biosimilar-and-biologics major with a comprehensive global portfolio, multi-plant biologics manufacturing, and scale-up specialty tranches needed CEO succession. The brief required biosimilar-and-biologics operating credibility, multi-product global-pipeline stewardship, capex-cycle discipline, and the governance rhythm of a listed biosimilar operator.
Outcome:
Placed a CEO with prior Head of Biologics tenure at a global biologics major and subsequent President tenure at a peer listed biosimilar operator. Search ran 176 days across a global talent architecture. Incoming CEO presented a multi-year global-pipeline-plus-manufacturing-capex plan within 90 days of joining.
Situation:
A pure-play biologics CDMO scaling its global-pharma-customer programme needed Head of Bioprocessing succession. The brief required upstream-and-downstream bioprocessing credibility, mammalian-cell-culture-and-aseptic-fill-finish architecture fluency, and the specific global-pharma-customer audit-posture architecture.
Outcome:
Placed a Head of Bioprocessing with prior head-of-bioprocess tenure at a global biologics major and subsequent head-of-operations tenure at a peer pure-play biologics CDMO. Engagement included a parallel Head of Aseptic Fill-Finish placement. CDMO won multiple global-pharma-customer mandates and scaled revenue by a meaningful multiple within 24 months of the Head's joining.
Situation:
A listed biosimilar operator preparing for multiple US-biosimilar launches needed Head of Commercialisation succession. The brief required US-biosimilar-launch credibility, global-partnership-and-licensing stewardship, specialty-distribution-and-payer-contracting discipline, and the specific biosimilar-uptake-and-switching-dynamics commercial rhythm.
Outcome:
Placed a Head of Commercialisation with prior head-of-commercialisation tenure at a global biosimilar major and subsequent VP-commercial tenure at an adjacent biosimilar operator. Multiple US-biosimilar launches completed on schedule with meaningful market-share capture within 18 months of the Head's joining.
All client details anonymised. Specific mandates available for reference under NDA upon request.
Our Biosimilars & Biologics Practice
Biosimilars-and-biologics represents the highest-value-per-molecule pharma tranche and India's emerging global competitive-position in biologics manufacturing and biosimilar development. The ecosystem spans listed biosimilar and biologics majors (the market-leading listed Indian biosimilars specialist with a comprehensive portfolio, the biologics arms of listed large-cap Indian pharma majors, and listed biosimilars-and-biologics arms of integrated listed pharma majors), pure-play biologics CDMOs (listed CRO-and-CDMO biologics specialists, listed integrated-biopharma manufacturing-and-vaccines operators, and privately-held biologics manufacturers), contract-research-and-manufacturing biologics specialists, recombinant-protein specialists (India units of global biologics MNCs, listed Indian biologics-and-vaccines specialists), monoclonal-antibody (mAb) specialists, emerging cell-and-gene-therapy specialists (India-domiciled cell-and-gene-therapy ventures and adjacent research-linked ventures), and emerging antibody-drug-conjugate (ADC) specialists. Leadership here requires fluency in biologics-manufacturing architecture (mammalian-cell-culture, microbial-fermentation), biosimilar-development-and-comparability protocol stewardship, WHO-prequalification and USFDA / EMA biosimilar-pathway compliance, cold-chain-and-supply-chain architecture, and the specific IP-and-patent-and-exclusivity architecture that defines biosimilar economics.
We place leaders across biosimilar and biologics majors, pure-play biologics CDMOs, recombinant-protein and mAb specialists, emerging cell-and-gene-therapy specialists, and ADC specialists. Engagements include CEO / MD searches, Head of Biosimilars / Head of Biologics / Business Head searches, Head of Biologics Manufacturing / Head of Bioprocessing searches, Head of Biologics R&D / Head of Cell-Line-Development searches, Head of Regulatory Affairs (Biosimilars / Biologics) searches, Head of Commercialisation and Head of Partnerships searches, and CFO placements with biologics-capex-and-investor-cycle credibility. Every mandate is retained and closed-network.
As a specialist CEO mandates in biologics, our practice also covers CTO and biotech R&D leadership, our practice also covers Pharmaceuticals & Biotech practice overview, and as a source for Healthcare & Life Sciences — clinical research.
The Biosimilars & Biologics Landscape Today
India's biologics-and-biosimilars industry has crossed $3 billion in domestic revenue and crossing $1.5-2 billion in exports, growing at 15-18% annually — meaningfully faster than the broader formulations industry. The market-leading listed Indian biosimilars specialist is a global leader among Indian biosimilar developers with an approved portfolio spanning trastuzumab, bevacizumab, pegfilgrastim, adalimumab, insulin-glargine, insulin-aspart, and a deep pipeline. A large-cap listed Indian pharma major has a material biosimilars business with a strong European-and-emerging-markets presence. Integrated listed pharma majors, listed biopharma-and-generics-API parents (via their biologics arms), and privately-held integrated-biologics operators have material biosimilars businesses. A listed CRO-and-CDMO biologics specialist is a leading pure-play biologics CDMO serving global-pharma customers for cell-line-development, bioprocessing, and GMP-manufacturing. Listed integrated-biopharma manufacturing-and-vaccines operators and privately-held biologics-and-vaccines operators run material biologics tranches (beyond their vaccine businesses). The global biosimilar market has crossed $50 billion with US-biosimilar approvals accelerating meaningfully — the adalimumab, bevacizumab, trastuzumab, rituximab, and pegfilgrastim biosimilar cycles have been structural positives for Indian operators. The emerging cell-and-gene-therapy tranche is nascent in India but materially scaling globally — India-domiciled cell-and-gene-therapy ventures and multiple academic-and-biotech ventures are building positions. The PLI Scheme for pharmaceuticals covers biologics and biosimilars with specific capex-and-production architecture. The NIPER and DBT-supported biosimilar-development architecture provides research-and-development support. Leadership in the sub-sector requires fluency in biologics-manufacturing (mammalian-cell-culture with CHO, NS0, BHK cell-lines; microbial-fermentation with E. coli, yeast), biosimilar-development-and-comparability protocols, WHO-prequalification / USFDA / EMA biosimilar-pathway compliance, cold-chain-and-supply-chain architecture, IP-and-patent-and-exclusivity architecture, and the specific investor-cadence of a capital-intensive sub-segment. Compensation is at the upper end of Indian pharma bands with specialty-and-complex-formulations premium.
Key Leadership Challenges in Biosimilars & Biologics
CEO / MD succession for listed biosimilar-and-biologics majors — leaders with biosimilar-and-biologics operating credibility, multi-product global-pipeline stewardship, capex-cycle discipline, and the governance rhythm of listed biosimilars operators.
Head of Biosimilars / Head of Biologics / Business Head placements — multi-product biosimilar-and-biologics operators need Business Heads with therapy-area-specific credibility (onco-mAbs, autoimmune-mAbs, insulins-and-GLP1s, pegylated-proteins).
Head of Biologics Manufacturing / Head of Bioprocessing placements — biologics manufacturers need Manufacturing Heads with upstream-and-downstream bioprocessing credibility, mammalian-cell-culture and microbial-fermentation architecture fluency, and the specific aseptic-fill-finish architecture of biologics manufacturing.
Head of Biologics R&D / Head of Cell-Line-Development placements — biologics operators need R&D Heads with cell-line-development, process-development, analytical-development, and comparability-protocol credibility.
Head of Regulatory Affairs (Biosimilars / Biologics) placements — biosimilar operators need RA Heads with USFDA 351(k) biosimilar-pathway credibility, EMA biosimilar-pathway stewardship, and the specific comparability-and-switching-studies regulatory architecture.
Head of Commercialisation / Head of Partnerships placements — biosimilar operators need Commercialisation Heads with global-partnership-and-licensing credibility and the specific regulated-markets-launch rhythm of biosimilars.
What We Look For in Biosimilars & Biologics Leaders
Across mandates, biosimilars & biologics leadership tends to cluster into a small set of archetypes. We calibrate each search against the profile your board actually needs — not the one most commonly available.
The Biosimilar / Biologics MD
Executive who has run a listed biosimilar-and-biologics major — fluent in biosimilar-and-biologics operating credibility, multi-product global-pipeline stewardship, capex-cycle discipline, IP-and-patent-exclusivity architecture, and the governance rhythm of listed biosimilar-and-biologics operators.
The Biosimilars / Biologics Business Head
Business-unit leader with therapy-area-specific biosimilar-and-biologics credibility (onco-mAbs, autoimmune-mAbs, insulins-and-GLP1s, pegylated-proteins, recombinant-proteins), global-commercial stewardship, and the specific regulated-markets-and-emerging-markets commercial rhythm of biosimilars.
The Biologics Manufacturing / Bioprocessing Head
Operations-led leader with upstream-and-downstream bioprocessing credibility, mammalian-cell-culture and microbial-fermentation architecture fluency, aseptic-fill-finish architecture stewardship, and the specific biosimilar-and-biologics-manufacturing rhythm. Fluent in single-use-bioreactor and stainless-steel-bioreactor operations.
The Biologics R&D / Cell-Line-Development Head
R&D leader with cell-line-development credibility, process-development stewardship, analytical-development architecture fluency, and the specific comparability-protocol and biosimilar-development rhythm. Often a PhD-qualified biotechnologist or molecular-biologist with subsequent Head of R&D leadership.
The Biosimilars / Biologics Regulatory Head
Leader with USFDA 351(k) biosimilar-pathway credibility, EMA biosimilar-pathway stewardship, comparability-and-switching-studies architecture fluency, and the specific post-approval-surveillance and immunogenicity-assessment rhythm of biosimilar regulatory affairs.
The Biosimilars Commercialisation / Partnerships Head
Commercial leader with global-partnership-and-licensing credibility, regulated-markets-launch-architecture fluency, specialty-distribution-and-payer-contracting stewardship, and the specific biosimilar-uptake-and-switching-dynamics commercial rhythm.
Regulatory & Compensation Context
Regulatory Backdrop
Biosimilars-and-biologics leadership operates within an especially dense regulatory envelope. The Drugs and Cosmetics Act 1940, the New Drugs and Clinical Trials Rules 2019, and the CDSCO Guidelines on Similar Biologics (2016, updated subsequently) govern biosimilar development, clinical trials, manufacturing, and approval in India. The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms / Genetically Engineered Organisms or Cells 1989 (administered by the Department of Biotechnology with the Genetic Engineering Appraisal Committee — GEAC, the Review Committee on Genetic Manipulation — RCGM, and Institutional Biosafety Committees — IBSCs) govern recombinant-DNA-technology operations. The Biological Diversity Act 2002 applies to specific bio-resource-utilisation cases. WHO Guidelines on evaluation of similar biotherapeutic products provide the global harmonisation baseline. The US architecture includes the Biologics Price Competition and Innovation Act (BPCIA) 2010, the 351(k) biosimilar-approval pathway, FDA guidance on biosimilar-and-interchangeability, and the Purple Book for biologic-and-biosimilar reference. The EU architecture includes EMA guidelines on similar biological medicinal products (the regulatory framework that pioneered biosimilars), country-specific procedures, and interchangeability frameworks (national-level post-2022 HMA-EMA reflection paper). The WHO Prequalification (PQ) of biologicals applies for multilateral-agency supply. ICH Q5A / Q5B / Q5C / Q5D / Q5E / Q6B govern biotechnological-product quality. PIC/S architecture and EU-GMP Annex 2 govern biological-manufacturing. Schedule M of the Drugs and Cosmetics Act (revised 2024) governs India-side GMP. USFDA 21 CFR Part 600 series governs US biologics manufacturing. The IP architecture — the Patents Act 1970 (including Section 3(d) and Section 3(j) for biological materials), BPCIA's 12-year-reference-product-exclusivity and 4-year-interchangeability exclusivity architecture, EU's SPC-plus-orphan-market-exclusivity architecture — defines biosimilar-economics windows. The Companies Act 2013 and SEBI LODR apply to listed biosimilar-and-biologics operators with specific pipeline-and-regulatory-milestone disclosure obligations. BRSR disclosure obligations apply to listed operators. For cell-and-gene-therapy, the Cell Therapy Regulations (draft / emerging), NIPER-and-DBT-administered institutional-framework, and global agencies' ATMP (Advanced Therapy Medicinal Products — EMA) / RMAT (Regenerative Medicine Advanced Therapy — USFDA) architectures apply. Candidates for senior roles are evaluated on their USFDA / EMA / WHO-PQ biosimilar-and-biologics submission-and-approval operating history, cell-line-and-bioprocess-development credibility, and the audit-and-regulatory-liaison posture they have run in prior operating roles.
Compensation Architecture
Biosimilars-and-biologics leadership compensation is at the upper end of Indian pharma bands with specialty-and-complex-formulations premium. MDs / CEOs of listed biosimilar-and-biologics majors command ₹12-30 crore total compensation (fixed ₹6-15 crore plus annual bonus and meaningful ESOPs / performance-share units). Heads of Biosimilars / Biologics at listed pharma majors' biologics tranches command ₹8-20 crore total compensation. Business Heads command ₹4-10 crore fixed with BU-P&L-linked variable. Heads of Biologics Manufacturing / Bioprocessing command ₹4-10 crore fixed — the USFDA-audit-credibility biologics Manufacturing Heads command the upper band. Heads of Biologics R&D / Cell-Line-Development command ₹4-10 crore fixed — the PhD-qualified biotechnology-credibility R&D Heads command the upper band. Heads of Regulatory Affairs (Biosimilars) command ₹4-9 crore fixed — the USFDA-351(k)-credibility RA Heads command the upper band. Heads of Commercialisation / Partnerships command ₹5-12 crore fixed with global-launch-linked variable. CFOs of listed biosimilar-and-biologics operators command ₹5-12 crore fixed with meaningful LTI. Emerging cell-and-gene-therapy leadership commands scale-up-pre-IPO architecture — CEOs command ₹5-12 crore fixed with meaningful founder-or-executive-equity (1-4% at entry-stage hiring). Retention architecture is the single most acute conversation in biologics — the competitive bid is cross-company (listed biosimilar majors, global biotech scaling India), cross-geography (US-and-EU-domiciled talent for specific roles), and cross-capital (listed platform, venture capital, growth equity).
Roles We Typically Place
Why Gladwin International Leadership Advisors for Biosimilars & Biologics
CEO / MD searches for listed and privately-held biosimilar-and-biologics operators.
Head of Biosimilars / Head of Biologics / Business Head / Head of Therapy Area placements.
Head of Biologics Manufacturing, Head of Bioprocessing, and Head of Aseptic Fill-Finish placements.
Head of Biologics R&D, Head of Cell-Line-Development, Head of Process Development, and Head of Analytical Development placements.
Head of Regulatory Affairs (Biosimilars / Biologics / USFDA 351(k) / EMA) placements.
Head of Commercialisation, Head of Partnerships, and Head of Licensing placements.
CFO and Head of IR placements for listed and pre-IPO biosimilar-and-biologics operators.
Organisations We Serve
Listed biosimilar-and-biologics majors (the market-leading listed Indian biosimilars specialist, biologics arms of listed large-cap Indian pharma majors, and listed biosimilars-and-biologics arms of integrated listed pharma majors)
Pure-play biologics CDMOs (listed CRO-and-CDMO biologics specialists, listed integrated-biopharma manufacturing-and-vaccines operators, and privately-held biologics manufacturers)
Recombinant-protein specialists and mAb specialists
Emerging cell-and-gene-therapy specialists (India-domiciled cell-and-gene-therapy ventures and adjacent biotech ventures)
Emerging antibody-drug-conjugate (ADC) specialists
Global biologics MNC India units and biologics operations of MNCs
PE-backed and venture-capital-backed biologics platforms
Biosimilars & Biologics leaders assessed on the Pharma & Biotech “HELIX” framework
Eight dimensions calibrated for pharmaceutical and biotechnology leadership. Dimensions are calibrated for biosimilars & biologics mandates where relevant.
Parent Practice
Return to Pharmaceuticals & Biotechnology
Discuss a Biosimilars & Biologics Mandate
Confidential · No obligation
Response within 4 business hours · All enquiries handled by a senior practice partner · Strictly confidential